Olivier Bylicki
Hôpital d'instruction des Armées Percy · 191 works · 3,988 citations · h-index 24
Top works
- Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
- LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)
- Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
- Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
- Efficacy and Safety of Anti–PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018
- Lung cancer trends and tumor characteristic changes over 20 years (2000–2020): Results of three French consecutive nationwide prospective cohorts’ studies
- Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer
- 1404P Clinical characteristics and therapeutics sequences of KRAS G12C metastatic non-small cell lung cancer (mNCSLC) patients treated by sotorasib in the French pre-marketing authorization (MA) early access program (cohort temporary authorization of use, cATU)
- Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy
- Impact of Tobacco Smoking on the Risk of COVID-19: A Large Scale Retrospective Cohort Study
- ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date
- ABO blood groups are not associated with risk of acquiring the SARS-CoV-2 infection in young adults
- Stay and play eFAST or scoop and run eFAST? That is the question!
- Positive FDG-PET/CT of the Pleura Twenty Years after Talc Pleurodesis: Three Cases of Benign Talcoma
- Temporary Endobronchial Embolization with Silicone Spigots for Moderate Hemoptysis: A Retrospective Study
- Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.
- Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial
- KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.
- Assessing the Multimodal Management of Advanced Solitary Fibrous Tumors of the Pleura in a Routine Practice Setting
- Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04–2021) trial